Compare Amphastar Pharmaceuticals Inc (AMPH) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Tripadvisor Inc Common Stock — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Tripadvisor Inc Common Stock trades at $13.89 (market cap $1.63B). The key difference: Tripadvisor Inc Common Stock is the larger of the two by market cap, and Tripadvisor Inc Common Stock is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | TRIP | |
|---|---|---|
Market Cap | $826.08M | $1.63B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $19.14 |
52-Week Low | $16.87 | $9.24 |
Enterprise Value | $1.22B | $1.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
TRIP trades at $13.98, up 4.88% today, near the consensus price target of $13.87. The stock shows a bullish technical signal with support at $13 and resistance at $14. Recent earnings have been mixed, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026. The company's $700 million sale of TheFork to American Express in June 2026 provides a cash infusion but highlights strategic refocusing amid competitive pressures.
The outlook is cautious; while the sale simplifies the business and boosts liquidity, core revenue growth remains modest and net margins are thin at 0.99%. Analyst sentiment is neutral with 60.72% hold ratings. Key risks include execution on the narrowed strategy and travel industry volatility. The stock appears fairly valued with a P/E of 127.09 reflecting low earnings, but the P/S of 0.93 suggests potential if top-line expansion accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
